Drugs / Convalescent Plasma of patients with COVID-19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04405310 | May → Nov 2020 | severe acute respiratory syndrome | Grupo Mexicano para el Estudio de la Medicina Intensiva | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Convalescent Plasma of patients with COVID-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04405310 ↗ |
| Route | Other | “Patients will receive 1 to 3 convalescent plasma transfusions, depending on the response to treatment.” NCT04405310 ↗ |